Related Experiment Video
Updated: Aug 20, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
Tau phosphatase activity as a therapeutic target for AD
1Dept. of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314, USA.
Abstract:
In the normal brain, tau promotes the assembly of tubulin into microtubules and maintains the structure of microtubules, which are required for axonal transport. Tau in AD brain is abnormally hyperphosphorylated ("AD P-tau") and does not promote the in vitro assembly of microtubules, bind to microtubules or stabilize their structure. Employing phosphorylation-dependent antibodies to tau, site-specific dephosphorylation of AD P-tau has been investigated. The phos-phoseryl/phosphothreonyl protein phosphatases (PSPs) PP-1, PP-2A and PP-2B rapidly dephosphorylated AD P-tau in vitro. The dephosphorylation of neurofibrillary tangles of paired helical filaments by the two major tau phosphatases, PP-2A and PP-2B, has been demonstrated to produce marked biochemical, biological and structural alterations. Thus, by increasing the activity of one more of these tau phosphatases, it might be possible to prevent and inhibit neuronal degeneration and consequently both the sporadic and the familial forms of AD.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Amplifying Signals via Enzymatic Cascade
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
PI3K/mTOR/AKT Signaling Pathway
